IP Library Granted Patent US 11,209,430
Granted Patent B2
US 11,209,430 · App. 16/654,988 · Granted Dec 28, 2021

Signal amplification in plasmonic specific-binding partner assays

Inventors: Rajesh K. Mehra (Union City, CA); Vincent Chiang (Union City, CA); Kenneth P. Aron (Union City, CA); Asher Krell (Union City, CA)
Assignee: ZOETIS SERVICES LLC
G01N33/553B82Y15/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,209,430
App. No.
16/654,988
Granted
Dec 28, 2021
Kind
B2
Abstract

The present invention relates to analyte detection devices and methods of using such devices to detect minute quantities of a target analyte in a sample. In particular, the invention provides an analyte detection device comprising a plurality of composite metallic nanostructures conjugated to analyte binding partners and a surface containing a metallic nanolayer on which a plurality of capture molecules is immobilized. Methods of preparing composite nanostructures are also described.

Claims (25)

1. A localized surface plasmon resonance (LSPR) assay complex comprising:

a plurality of detection conjugates, wherein each detection conjugate comprises a composite metallic nanostructure coupled to a binding partner, wherein said binding partner is capable of specifically binding to a target analyte, wherein said composite metallic nanostructure comprises a silver core and a gold coating;

a surface containing a metallic nanolayer; and

a plurality of capture molecules, wherein each capture molecule is immobilized on said metallic nanolayer and is capable of specifically binding to said target analyte.

2. The LSPR assay complex of claim 1 , wherein said composite metallic nanostructure is a spherical nanoparticle having a diameter ranging from about 5 nm to about 200 nm.

3. The LSPR assay complex of claim 1 , wherein said composite metallic nanostructure is a spherical nanoparticle having a diameter ranging from about 10 nm to about 100 nm.

4. The LSPR assay complex of claim 1 , wherein said composite metallic nanostructure is a nanoplate having an edge length ranging from about 10 nm to about 800 nm and a thickness ranging from about 1 nm to about 100 nm.

5. The LSPR assay complex of claim 1 , wherein said plurality of detection conjugates are in the form of a lyophilized pellet or bead.

6. The LSPR assay complex of claim 1 , wherein said surface is on a chip, a well, a bead, a wall, a cover, or a bottom of a cuvette.

7. The LSPR assay complex of claim 1 , wherein said metallic nanolayer is a metallic film.

8. The LSPR assay complex of claim 7 , wherein said metallic film comprises gold, silver, copper, platinum, palladium, cadmium, zinc or a combination thereof.

9. The LSPR assay complex of claim 7 , wherein said metallic film comprises gold.

10. The LSPR assay complex of claim 1 , wherein said metallic nanolayer comprises a plurality of metallic nanostructures immobilized on said surface.

11. The LSPR assay complex of claim 10 , wherein each of said plurality of metallic nanostructures comprises gold, silver, copper, platinum, palladium, cadmium, zinc or a combination thereof.

12. The LSPR assay complex of claim 10 , wherein each of said plurality of metallic nanostructures is a gold nanostructure.

13. The LSPR assay complex of claim 1 , wherein said composite metallic nanostructure has a geometry selected from a spherical nanoparticle, a pyramidal nanoparticle, a hexagonal nanoparticle, a nanoshell, a nanotube, a nanorod, a nanodot, a nanoisland, a nanowire, or a combination thereof.

14. The LSPR assay complex of claim 1 , wherein said binding partner is an antibody, an antigen, a polypeptide, a polynucleotide, a nucleoprotein, an aptamer, a ligand, a receptor, or a hapten.

15. The LSPR assay complex of claim 1 , wherein said capture molecule is an antibody, an antigen, a polypeptide, a polynucleotide, a nucleoprotein, an aptamer, a ligand, a receptor, or a hapten.

16. The LSPR assay complex of claim 1 , wherein said binding partner is an antibody that recognizes a first epitope of said target analyte and said capture molecule is a different antibody that recognizes a second epitope of said target analyte.

17. The LSPR assay complex of claim 1 , wherein said target analyte is a marker or an antigen associated with an infectious disease, physiological state, or pathological condition.

18. The LSPR assay complex of claim 1 , wherein said target analyte is a canine heartworm molecule, a feline leukemia virus molecule, a canine parvovirus molecule, a C-reactive protein, a Giardia lamblia molecule, an Ehrlichia antigen or antibody, a Borrelia antigen or antibody, an Anaplasma antigen or antibody, a cancer antigen, a cardiac marker antigen, a thyroid stimulating hormone, thyroxine, troponin, or a brain natriuretic peptide.

19. A localized surface plasmon resonance (LSPR) assay complex comprising:

a plurality of detection conjugates, wherein each detection conjugate comprises a composite metallic nanostructure coupled to a target analyte, wherein said composite metallic nanostructure comprises a silver core and a gold coating;

a surface containing a metallic nanolayer; and

a plurality of capture molecules, wherein each capture molecule is immobilized on said metallic nanolayer and is capable of specifically binding to said target analyte.

Assignments (3)
CHANGE OF NAME Recorded Feb 1, 2021
From: ABAXIS, INC.
To: ABAXIS LLC
Reel/Frame 055191/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2021
From: ABAXIS LLC
To: ZOETIS SERVICES LLC
Reel/Frame 055191/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2019
From: MEHRA, RAJESH K.; CHIANG, VINCENT; ARON, KENNETH P.; KRELL, ASHER
To: ABAXIS, INC.
Reel/Frame 050784/0951 →
Continuity (4)
Division 14825668 · Aug 13, 2015
Provisional Application 62037071 · Aug 13, 2014
Provisional Application 62082468 · Nov 20, 2014
Related Publication 20200150115A1 · May 14, 2020
Cited By (1)
US 12,704,510